182 related articles for article (PubMed ID: 14706487)
1. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) topography predicts treatment response to methylphenidate.
Sangal RB; Sangal JM
Clin Neurophysiol; 2004 Jan; 115(1):188-93. PubMed ID: 14706487
[TBL] [Abstract][Full Text] [Related]
2. Attention-deficit/hyperactivity disorder: cognitive evoked potential (P300) amplitude predicts treatment response to atomoxetine.
Sangal RB; Sangal JM
Clin Neurophysiol; 2005 Mar; 116(3):640-7. PubMed ID: 15721078
[TBL] [Abstract][Full Text] [Related]
3. Attention-deficit/hyperactivity disorder: use of cognitive evoked potential (P300) to predict treatment response.
Sangal RB; Sangal JM
Clin Neurophysiol; 2006 Sep; 117(9):1996-2006. PubMed ID: 16890481
[TBL] [Abstract][Full Text] [Related]
4. Abnormal auditory P300 topography in attention deficit disorder predicts poor response to pemoline.
Sangal JM; Sangal RB; Persky B
Clin Electroencephalogr; 1995 Oct; 26(4):204-13. PubMed ID: 8575100
[TBL] [Abstract][Full Text] [Related]
5. Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine.
Sangal JM; Sangal RB; Persky B
Clin Electroencephalogr; 1996 Oct; 27(4):191-201. PubMed ID: 9465283
[TBL] [Abstract][Full Text] [Related]
6. Effects of osmotic-release methylphenidate in attention-deficit/hyperactivity disorder as measured by event-related potentials.
Sawada M; Iida J; Ota T; Negoro H; Tanaka S; Sadamatsu M; Kishimoto T
Psychiatry Clin Neurosci; 2010 Oct; 64(5):491-8. PubMed ID: 20923428
[TBL] [Abstract][Full Text] [Related]
7. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention-deficit/hyperactivity disorder.
Schulz KP; Fan J; Bédard AC; Clerkin SM; Ivanov I; Tang CY; Halperin JM; Newcorn JH
Arch Gen Psychiatry; 2012 Sep; 69(9):952-61. PubMed ID: 22945622
[TBL] [Abstract][Full Text] [Related]
8. Effect of methylphenidate on auditory event related potential in boys with attention deficit hyperactivity disorder.
Ozdag MF; Yorbik O; Ulas UH; Hamamcioglu K; Vural O
Int J Pediatr Otorhinolaryngol; 2004 Oct; 68(10):1267-72. PubMed ID: 15364497
[TBL] [Abstract][Full Text] [Related]
9. Changes of the brain electrical fields during the continuous performance test in attention-deficit hyperactivity disorder-boys depending on methylphenidate medication.
Zillessen KE; Scheuerpflug P; Fallgatter AJ; Strik WK; Warnke A
Clin Neurophysiol; 2001 Jul; 112(7):1166-73. PubMed ID: 11516728
[TBL] [Abstract][Full Text] [Related]
10. Electrophysiological indices of information processing in methylphenidate responders.
Winsberg BG; Javitt DC; Silipo GS
Biol Psychiatry; 1997 Sep; 42(6):434-45. PubMed ID: 9285079
[TBL] [Abstract][Full Text] [Related]
11. Response to growth hormone in attention deficit hyperactivity disorder: effects of methylphenidate and pemoline therapy.
Rao JK; Julius JR; Breen TJ; Blethen SL
Pediatrics; 1998 Aug; 102(2 Pt 3):497-500. PubMed ID: 9685452
[TBL] [Abstract][Full Text] [Related]
12. Event-related potentials reflect the efficacy of pharmaceutical treatments in children and adolescents with attention deficit/hyperactivity disorder.
Yamamuro K; Ota T; Iida J; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto N; Tanaka S; Kishimoto T
Psychiatry Res; 2016 Aug; 242():288-294. PubMed ID: 27318633
[TBL] [Abstract][Full Text] [Related]
13. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder.
Stevenson RD; Wolraich ML
Pediatr Clin North Am; 1989 Oct; 36(5):1183-97. PubMed ID: 2677938
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder.
Castellanos FX; Elia J; Kruesi MJ; Marsh WL; Gulotta CS; Potter WZ; Ritchie GF; Hamburger SD; Rapoport JL
Neuropsychopharmacology; 1996 Feb; 14(2):125-37. PubMed ID: 8822535
[TBL] [Abstract][Full Text] [Related]
15. Attention-deficit/hyperactivity disorder: using P300 topography to choose optimal treatment.
Sangal RB; Sangal JM
Expert Rev Neurother; 2006 Oct; 6(10):1429-37. PubMed ID: 17078784
[TBL] [Abstract][Full Text] [Related]
16. Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.
Rubia K; Halari R; Cubillo A; Mohammad AM; Brammer M; Taylor E
Neuropharmacology; 2009 Dec; 57(7-8):640-52. PubMed ID: 19715709
[TBL] [Abstract][Full Text] [Related]
17. [Studies of evoked potentials in children with the syndrome of attention deficit and hyperactivity].
Smeyers P
Rev Neurol; 1999 Feb; 28 Suppl 2():S173-6. PubMed ID: 10778509
[TBL] [Abstract][Full Text] [Related]
18. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
19. [The value of cognitive evoked potentials in assessing the effectiveness of methylphenidate treatment in children with attention deficit hyperactivity disorder].
Idiazábal-Alecha MA; Rodríguez-Vázquez S; Guerrero-Gallo D; Vicent-Sardinero X
Rev Neurol; 2005 Jan; 40 Suppl 1():S37-42. PubMed ID: 15736091
[TBL] [Abstract][Full Text] [Related]
20. Aerobic exercise and attention deficit hyperactivity disorder: brain research.
Choi JW; Han DH; Kang KD; Jung HY; Renshaw PF
Med Sci Sports Exerc; 2015 Jan; 47(1):33-9. PubMed ID: 24824770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
